ScholarIQanswers from OpenAlex
Boehringer Ingelheim
FunderResearch funding and supported work
Boehringer Ingelheim is a funder indexed in ScholarIQ from OpenAlex.
How many works does Boehringer Ingelheim have?
ScholarIQindexed works
Boehringer Ingelheim has 4,779 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Boehringer Ingelheim?
ScholarIQopenalex
The OpenAlex for Boehringer Ingelheim is on the source record.
What is the ROR of Boehringer Ingelheim?
ScholarIQror
The ROR for Boehringer Ingelheim is on the source record.
What are the most-cited papers on Boehringer Ingelheim?
ScholarIQmost cited works
Empagliflozin after Acute Myocardial Infarction
Javed Butler, W. Schuyler Jones, Jacob A. Udell, Stefan D. Anker, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Isabella Zwiener, Offer Amir, M. Cecilia Bahit, Johann Bauersachs, Antoni Bayés‐Genís, Yundai Chen, Vijay Chopra, Gemma A. Figtree, Junbo Ge, Shaun G. Goodman, Nina Gotcheva, Shinya Goto, Tomasz Gąsior, Waheed Jamal, James L. Januzzi, Myung Ho Jeong, Yu. M. Lopatin, Renato D. Lópes, Béla Merkely, Puja B. Parikh, Alexander Parkhomenko, Piotr Ponikowski, Xavier Rosselló, Morten Schou, Dragan Šimić, Philippe Gabríel Steg, Joanna Szachniewicz, Peter van der Meer, Dragoş Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
Li Shen, Søren Lund Kristensen, Olof Bengtsson, Michael Böhm, Rudolf A. de Boer, Kieran F. Docherty, Silvio E. Inzucchi, Tzvetana Katova, Lars Køber, Mikhail Kosiborod, Anna Maria Langkilde, Daniel Lindholm, M. Felipe A. Martinez, Eileen O’Meara, José Carlos Nicolau, Mark C. Petrie, Piotr Ponikowski, Marc S. Sabatine, Morten Schou, Mikaela Sjöstrand, Scott D. Solomon, Pardeep S. Jhund, John J.V. McMurray
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease
Iris E. Beldhuis, Peder L. Myhre, Brian Claggett, Kevin Damman, James C. Fang, Eldrin F. Lewis, Eileen O’Meara, Bertram Pitt, Sanjiv J. Shah, Adriaan A. Voors, Marc A. Pfeffer, Scott D. Solomon, Akshay S. Desai
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
Adeera Levin, Vlado Perkovic, David C. Wheeler, Stefan Hantel, Jyothis T. George, Maximilian von Eynatten, Audrey Koitka‐Weber, Christoph Wanner, on behalf of the EMPA-REG OUTCOME Investigators
Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction
Rahul Aggarwal, Deepak L. Bhatt, Adrian F. Hernandez, Stefan D. Anker, Josephine Harrington, W. Schuyler Jones, Michaela Mattheus, Mark C. Petrie, Dominik Steubl, Mikhail Sumin, Vikram Thanam, Jacob A. Udell, Javed Butler